October 12, 2020
3 min watch
Save
VIDEO: Stelara shows ‘remarkable durability’ in Crohn’s
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this exclusive video from UEG Week Virtual, William J. Sandborn, MD, from the University of California, San Diego, discusses the final results from the IM-UNITI long-term extension trial of Stelara in patients with Crohn’s disease.
In the study, researchers found that nearly half of patients with CD who responded to Stelara (ustekinumab, Janssen) in induction were in remission after 5 years of maintenance treatment. Additionally, they found no new safety signals.
Published by:
Sources/Disclosures
Collapse
Source:
Sandborn W, et al. Abstract OP110. Presented at: UEG Week Virtual. Oct. 11-13.
Disclosures:
This study was supported by Janssen Research & Development
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.